Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy.
BACKGROUND
Data on initial antiretroviral regimen longevity predates the arrival of newer nucleoside reverse transcriptase inhibitor backbones and once-daily regimens. Modern regimens are thought to possess greater tolerability and convenience. We hypothesized this would translate into greater durability.


METHODS
Retrospective study of antiretroviral-naive patients starting treatment at the University of Alabama at Birmingham 1917 HIV/AIDS Clinic 1 January 2000-31 July 2007. Two periods of antiretroviral initiation were identified, prior and after August 2004 (arrival of once-daily fixed-dose regimens). Kaplan-Meier survival analyses of regimen durability by time period and regimen characteristics were performed. Staged Cox proportional hazards models evaluated the roles of dosing complexity and composition in explaining differences in regimen durability between study periods.


RESULTS
Overall 542 patients started antiretroviral drugs (n = 309, January 2000-July 2004; n = 233, August 2004-July 2007). Median durability was 263 days longer in after August 2004 regimens. Regimens started before August 2004 had increased hazards for discontinuation relative to after August 2004 regimens [hazard ratio (HR) = 1.44; 95% confidence interval (CI) = 1.03-2.02]. Time period of initiation lost statistical significance when the model included dosing frequency (HR = 1.92 for at least twice daily vs. daily; 95% CI = 1.29-2.88). As regimen composition variables were added, time period and dosing frequency lost significance. Increased hazards of discontinuation were observed with didanosine or stavudine relative to abacavir or tenofovir use (HR = 1.92; 95% CI = 1.29-2.88) and all third drugs compared with non-nucleoside reverse transcriptase inhibitor-based regimens (triple-nucleoside reverse transcriptase inhibitor HR = 1.76; 95% CI = 1.14-2.73; unboosted-protease inhibitor HR = 1.58; 95% CI = 1.02-2.46; boosted-protease inhibitor HR = 1.57; 95% CI = 1.02-2.41). Affective mental health disorders increased the hazard of discontinuation in all models.


CONCLUSIONS
Durability of contemporary once-daily fixed-dose antiretroviral regimens has significantly eclipsed the duration of earlier antiretroviral drug options. Our results indicate this is due to both more convenient dosing and improved tolerability of modern antiretroviral regimens.
Willig
James H
JH
Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. jwillig@uab.edu
Abroms
Sarah
S
Westfall
Andrew O
AO
Routman
Justin
J
Adusumilli
Sunil
S
Varshney
Mohit
M
Allison
Jeroan
J
Chatham
Ashlee
A
Raper
James L
JL
Kaslow
Richard A
RA
Saag
Michael S
MS
Mugavero
Michael J
MJ
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D018791:CD4 Lymphocyte Count; D004334:Drug Administration Schedule; D004812:Epidemiologic Methods; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors
AIDS. 2006 Jun 26;20(10):1407-14
16791015
Braz J Infect Dis. 2002 Dec;6(6):298-304
12585973
AIDS Res Hum Retroviruses. 2005 Jun;21(6):527-36
15989457
J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):159-66
17146374
AIDS. 2005 Jan 3;19(1):15-23
15627029
AIDS. 2007 Jan 11;21(2):169-78
17197807
HIV Med. 2006 Apr;7(3):156-62
16494629
AIDS. 2001 Jan 26;15(2):185-94
11216926
J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):384-90
18091609
JAMA. 2006 Aug 16;296(7):827-43
16905788
Clin Infect Dis. 2003 Sep 1;37(5):714-22
12942406
AIDS. 2000 Mar 31;14(5):499-507
10780712
AIDS. 2007 May 31;21(9):1175-83
17502728
Drugs. 2007;67(14):1969-79
17883282
Med Clin (Barc). 2006 Feb 25;126(7):241-5
16510064
N Engl J Med. 2006 Nov 30;355(22):2283-96
17135583
Antivir Ther. 2007;12(3):407-15
17591031
Ann Intern Med. 2007 May 1;146(9):682-3
17470837
Pharmacotherapy. 2006 May;26(5):674-81
16637796
AIDS. 2002 Aug 16;16(12):1617-26
12172083